PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Non-Hodgkin's LymphomaMyelomaActive Solid Malignancy
Interventions
DRUG

PET Imaging using 124 IPUH71

A dose of up to 11.0 mCi (range: 4.0-11.0 mCi) of 124I-PUH71 will be administered intravenously with the patient at rest. 124I-PUH71 scans will be performed at immediately and/or 3-4 hours, 20-24 hours, and 40-80 hours after injection of the radiotracer. Optionally, in willing patients scans will be performed 160-200 hours (\~7-8 days) after injection of the radiotracer. At each time-point, a 45-60 minute axial body image is acquired. Images will be acquired on a state-of-the-art PET-CT scanner. A low-dose CT will be obtained immediately-prior to PET imaging, at each time-point. A 30-45 minute scanning timeperiod is typical for clinical PET studies.

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Samus Therapeutics

UNKNOWN

lead

Memorial Sloan Kettering Cancer Center

OTHER